

# Development of the symptoms and impacts questionnaire for ulcerative colitis

Alimentary Pharmacology and Therapeutics

51, 1047-1066

DOI: [10.1111/apt.15726](https://doi.org/10.1111/apt.15726)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1047-1066.	1.9	33
2	Risks of under-treating and over-treating disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 29-29.	1.4	0
3	Challenges and Opportunities in IBD Clinical Trial Design. <i>Gastroenterology</i> , 2021, 161, 400-404.	0.6	11
4	Web-based and machine learning approaches for identification of patient-reported outcomes in inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2022, 54, 483-489.	0.4	2
5	Mucosal Healing in Crohn's Disease: Bull's Eye or Bust? The "Relative" Con Position. <i>Inflammatory Intestinal Diseases</i> , 2022, 7, 1-8.	0.8	1
6	Updates in Clinical, Endoscopic, and Histologic Composite and Co-primary Endpoints for Clinical Trials in Inflammatory Bowel Disease. <i>Current Treatment Options in Gastroenterology</i> , 2021, 19, 608.	0.3	1
7	Systematic review: disease activity indices for immune checkpoint inhibitor-associated enterocolitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 178-190.	1.9	6
8	The Future of Precision Medicine to Predict Outcomes and Control Tissue Remodeling in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2022, 162, 1525-1542.	0.6	23
10	Incorporating patient experience into drug development for ulcerative colitis: development of the Urgency Numeric Rating Scale, a patient-reported outcome measure to assess bowel urgency in adults. <i>Journal of Patient-Reported Outcomes</i> , 2022, 6, 31.	0.9	21
11	Heterogeneity in outcome assessment for inflammatory bowel disease in routine clinical practice: a mixed-methods study in a sample of English hospitals. <i>BMJ Open</i> , 2021, 11, e056413.	0.8	3
12	Impact of Bowel Urgency on Quality of Life and Clinical Outcomes in Patients With Ulcerative Colitis. <i>Crohn's &amp; Colitis 360</i> , 2022, 4, .	0.5	8
13	Computable Phenotype of a Crohn's Disease Natural History Model. <i>Medical Decision Making</i> , 2022, 42, 937-944.	1.2	1
14	<i>Hypericum sampsonii</i> attenuates inflammation in mice with ulcerative colitis via regulation of PDE4/PKA/CREB signaling pathway. <i>Journal of Ethnopharmacology</i> , 2022, 296, 115447.	2.0	6
15	CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2022, 163, 950-964.	0.6	29
16	Development of a Core Outcome Set for Real-world Data in Inflammatory Bowel Disease: A European Crohn's and Colitis Organisation [ECCO] Position Paper. <i>Journal of Crohn's and Colitis</i> , 2023, 17, 311-317.	0.6	7
17	Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 <sc>MOTIVATE</sc>, <sc>ADVANCE</sc> and <sc>FORTIFY</sc> clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 496-508.	1.9	3
18	Patient-Reported Impact of Symptoms in Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2022, 117, 2033-2045.	0.2	7
19	Psychometric evaluation of the Urgency NRS as a new patient-reported outcome measure for patients with ulcerative colitis. <i>Journal of Patient-Reported Outcomes</i> , 2022, 6, .	0.9	3

#	ARTICLE	IF	CITATIONS
20	Principles for Assessing Quality of Life in Patients With Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2022, 117, 1952-1953.	0.2	0
21	Clinical Effect of Mirikizumab Treatment on Bowel Urgency in Patients with Moderately to Severely Active Ulcerative Colitis and the Clinical Relevance of Bowel Urgency Improvement for Disease Remission. <i>Crohn's &amp; Colitis</i> 360, 2023, 5, .	0.5	8
22	International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients. <i>Medicina (Lithuania)</i> , 2023, 59, 183.	0.8	4
23	S753 Mirikizumab Significantly Improves Abdominal Pain in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies. <i>American Journal of Gastroenterology</i> , 2022, 117, e533-e534.	0.2	0
24	Randomised clinical trial: Psychological intervention improves work productivity and daily activity by reducing abdominal pain and fatigue in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 861-871.	1.9	2
25	Meta-analysis: Placebo rates in microscopic colitis randomised trials and applications for future drug development using a historical control arm. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 837-850.	1.9	1
26	Identifying, Understanding, and Managing Fecal Urgency in Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1403-1413.e27.	2.4	5